Off-Label Use of Atypical Antipsychotics: An Update
Trends in Off-Label Use of Atypical Antipsychotics
Since the FDA regulatory warning in 2005 about severe adverse events in the elderly (ages ≥65), the use of atypical antipsychotics for treating the elderly has declined. However, the statistical significance of the change is not known.
Off-label use of atypical antipsychotics is higher in long-term care settings than in the community.
No off-label use of the most recently approved atypical antipsychotics (asenapine, iloperidone, and paliperidone) has been reported in the literature.
Risperidone, quetiapine, and olanzapine are the most commonly prescribed atypical antipsychotics for off-label indications.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | prescribing | asenapine | iloperidone | paliperidone | risperidone | quetiapine | olanzapine
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.